<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04783675</url>
  </required_header>
  <id_info>
    <org_study_id>RTXFIRPedINS</org_study_id>
    <nct_id>NCT04783675</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Rituximab in the First Episode of Pediatric Idiopathic Nephrotic Syndrome</brief_title>
  <acronym>RTXFIRPedINS</acronym>
  <official_title>Efficacy and Safety of Rituximab in the First Episode of Pediatric Idiopathic Nephrotic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital of Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Children's Hospital of Zhejiang University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anhui Provincial Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Affiliated to Zhengzhou University/Henan Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to demonstrate, from the initial episode of nephrotic syndrome (NS) in&#xD;
      children with standard prednisolone treatment, once complete remission has occurred, that the&#xD;
      use of Rituximab (a single intravenous infusion of 375 mg/m2) may reduce the risk of&#xD;
      subsequent relapse during 12-month of follow-up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NS is the most frequent glomerular disease in children. Between 80% and 90% of children with&#xD;
      steroid-sensitive nephrotic syndrome (SSNS) will relapse following an initial response to&#xD;
      corticosteroids. Half of these children will experience frequent relapses (FRNS) or become&#xD;
      steroid-dependent (SDNS).&#xD;
&#xD;
      The results of multiple observational studies and randomized control trials have shown that&#xD;
      Rituximab, a chimeric monoclonal antibody against the cluster of differentiation antigen 20&#xD;
      (CD20) antigen on B cells, is safe and effective for children with FRNS/SDNS without&#xD;
      corticosteroid or immunosuppressive therapy. To the investigators' knowledge, Rituximab has&#xD;
      never been investigated for the initial episode of NS with the aim to reduce the subsequent&#xD;
      risk of relapse that is a major concern in the management of children with NS.&#xD;
&#xD;
      Children aged 1-18 years with the first episode of the SSNS will be treated with a single&#xD;
      intravenous infusion of Rituximab 375 mg/m2. The prednisolone at a dose of 2 mg/kg per day&#xD;
      (maximum 60 mg in single or divided doses) for 6 weeks, followed by 1.5 mg/kg (maximum 40 mg)&#xD;
      as a single morning dose on alternate days for the next 6 weeks; therapy is then&#xD;
      discontinued.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 13, 2021</start_date>
  <completion_date type="Anticipated">May 24, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 24, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Rituximab</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year relapse-free survival rate</measure>
    <time_frame>1-year period after randomization</time_frame>
    <description>The rate of no relapse within 1 year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to relapse (days)</measure>
    <time_frame>1-year period after administration of rituximab therapy</time_frame>
    <description>Number of days from randomization to occurrence of first relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a relapse</measure>
    <time_frame>6 months period after administration of rituximab therapy</time_frame>
    <description>The proportion of patients with relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-Cell Recovery Time</measure>
    <time_frame>1-year period after administration of rituximab therapy</time_frame>
    <description>Time to the first detection of CD19+ cells above 1% of total CD45+ lymphocytes after CD19+ cell depletion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of rituximab on peripheral blood B cell subsets and T cell subsets to highlight biomarkers useful for monitoring response to rituximab treatment.</measure>
    <time_frame>1-year period after administration of rituximab therapy</time_frame>
    <description>Using fluorescence-activated cell sorting (FACS), peripheral blood B cell subsets and T cell subsets will be measured as at baseline, before and after infusion of rituximab at 3,6,12 months, and when relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>1-year period after administration of rituximab therapy</time_frame>
    <description>It is a binary variable (1/0). The varibale would be setted as &quot;1&quot; if any adverse events occours including infusion-related reactions, infection (upper respiratory tract infection, hepatitis B virus reactivation, herpes zoster infection, pneumocystis pneumonia, etc), persistent hypogammaglobulinaemia, encephalopathy, severe neutropenia, fatal pulmonary fibrosis, ulcerative colitis, Crohn's disease and fulminant myocarditis etc. Adverse events will be graded according to the Common Terminology Criteria for Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Steroid-Sensitive Nephrotic Syndrome</condition>
  <arm_group>
    <arm_group_label>Intervention/treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab (375 mg/m2) will be given as a single intravenous infusion after remission</description>
    <arm_group_label>Intervention/treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Children between 1 and 18 years with Steroid-Sensitive Nephrotic Syndrome&#xD;
&#xD;
          -  2. Estimated glomerular filtration rate (eGFR) ≥90 ml/min per 1.73 m2 at study entry.&#xD;
&#xD;
          -  3. Remission at study entry&#xD;
&#xD;
          -  4.CD20 positive cells in peripheral blood ≥1% total lymphocytes&#xD;
&#xD;
          -  5.No immunosuppressive agents have been used within 3 months of enrollment, except for&#xD;
             the use of corticosteroid to treat nephrotic syndrome.&#xD;
&#xD;
          -  6. Provision of consent by a legal representative (parents or legal guardians) using a&#xD;
             document approved by the institutional review board after receiving an adequate&#xD;
             explanation regarding the implementation of this clinical trial. For children/youth&#xD;
             ages 10-18, written assent is required using age-appropriate and&#xD;
             background-appropriate documents.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1.Diagnosis of secondary NS&#xD;
&#xD;
          -  2.Patients showing one of the following abnormal clinical laboratory values:&#xD;
             leukopenia (white blood cell count ≤3.0*109/L); moderate and severe anemia (hemoglobin&#xD;
             &lt;9.0g/dL); thrombocytopenia (platelet count &lt;100*1012/ L); positivity of autoimmunity&#xD;
             tests (ANA, Anti DNA antibody, ANCA) or reduced C3 levels; Positive for hepatitis B&#xD;
             surface (HBs) antigen, HBs antibody, hepatitis B core (HBc) antibody, or hepatitis C&#xD;
             virus (HCV) antibody ; Positive for HIV antibody; Alanine aminotransferase (ALT) &gt;&#xD;
             2.5× upper limit of normal value. Aspartate aminotransferase (AST) &gt; 2.5× upper limit&#xD;
             of normal value.&#xD;
&#xD;
          -  3. Presence or history of severe or opportunistic infections within 6 months before&#xD;
             assignment; Presence of active tuberculosis or with a history of tuberculosis or in&#xD;
             whom tuberculosis is suspected; Presence or history of chronic active infections such&#xD;
             as Epstein-Barr virus and CMV virus; presence or history of active hepatitis B or&#xD;
             hepatitis C or hepatitis B virus carrier. Presence of human immunodeficiency virus&#xD;
             (HIV) infection or other active viral infections&#xD;
&#xD;
          -  4. Receipt of a live vaccine within 4 weeks before enrollment.&#xD;
&#xD;
          -  5. Prior receipt of monoclonal antibodies of any type&#xD;
&#xD;
          -  6. History of angina pectoris, cardiac failure, myocardial infarction, or serious&#xD;
             arrhythmia，or poorly controlled hypertension&#xD;
&#xD;
          -  7. Presence or history of autoimmune diseases or vascular purpura.&#xD;
&#xD;
          -  8. Presence or history of malignant tumor&#xD;
&#xD;
          -  9. History of organ transplantation (excluding corneal and hair transplants).&#xD;
&#xD;
          -  10. Patients with a known allergy to steroid and their excipients or to Rituximab and&#xD;
             its excipients or to acetaminophen and its excipients or to cetirizine and its&#xD;
             excipients or to the protein of murine origin&#xD;
&#xD;
          -  11. Assessed to be unfit for participation by the investigators&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xu Hong, PhD.MD.</last_name>
    <phone>+8602164932829</phone>
    <email>hxu@shmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shen qian, PhD.MD.</last_name>
    <phone>+8602164932827</phone>
    <email>shenqian@shmu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Anhui Provincial Children's Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deng Fang</last_name>
    </contact>
    <contact_backup>
      <last_name>Zhou huiqin</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Affiliated to Zhengzhou University/Henan Children's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liu Cuihua</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuhan Children's Hospital,Tongji Medical College, Huazhong University of Science and Technology.</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wang Xiaowen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhang Aihua</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mao Jianhua</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>201102</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xu Hong, PhD,MD</last_name>
      <phone>+86-02164932829</phone>
      <email>hxu@shmu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Children's Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wu Ying</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xinhua Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Yufeng</last_name>
      <phone>+8613651722016</phone>
      <email>liyufeng@xinhuamed.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 28, 2021</study_first_submitted>
  <study_first_submitted_qc>March 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

